Evidence map›Paper›PMID 32769117›Full record

ArticleThe Journal of biological chemistry2020

The inhibition of cellular toxicity of amyloid-β by dissociated transthyretin.

Qin Cao, Daniel H Anderson, Wilson Y Liang, Joshua Chou, Lorena Saelices

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Photolytic disruption of Alzheimer's amyloid AβCommunications chemistry · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Conformational inhibitors of protein aggregation.Current opinion in structural biology · 2023
    Review
  7. Article
  8. Article
  9. Protein Interactome of Amyloid-β as a Therapeutic Target.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  10. Review
  11. Amyloidogenesis: What Do We Know So Far?International journal of molecular sciences · 2022
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Qin CaoDepartment of Biological Chemistry, Molecular Biology Institute, University of California, Los Angeles, Los Angeles, California, USA.
Daniel H AndersonDepartment of Biological Chemistry, Molecular Biology Institute, University of California, Los Angeles, Los Angeles, California, USA.
Wilson Y LiangDepartment of Biological Chemistry, Molecular Biology Institute, University of California, Los Angeles, Los Angeles, California, USA.
Joshua ChouDepartment of Biological Chemistry, Molecular Biology Institute, University of California, Los Angeles, Los Angeles, California, USA.ORCID 0000-0001-5616-4870
Lorena SaelicesDepartment of Biological Chemistry, Molecular Biology Institute, University of California, Los Angeles, Los Angeles, California, USA Lorena.SaelicesGomez@UTSouthwestern.edu.
University of California, Los Angeles · US

Funding

Closing the gap between structural biology and translational science for amyloid diseasesDP2HL163810 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI SAELICES GOMEZ, LORENA · 2021 to 2024
$2.5M
NHLBI NIH HHS DP2 HL163810
6 · The paper itself

Abstract

The protective effect of transthyretin (TTR) on cellular toxicity of β-amyloid (Aβ) has been previously reported. TTR is a tetrameric carrier of thyroxine in blood and cerebrospinal fluid, the pathogenic aggregation of which causes systemic amyloidosis. However, studies have documented a protective effect of TTR against cellular toxicity of pathogenic Aβ, a protein associated with Alzheimer's disease. TTR binds Aβ, alters its aggregation, and inhibits its toxicity both

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesMolecular Docking SimulationPrealbuminProtein Aggregation, PathologicalAged, 80 and overBinding SitesCell LineFemaleHumansAmyloid beta-PeptidesPrealbuminTTR protein, humanAlzheimer's diseaseamyloidamyloid-beta (AB)cytotoxicityneuroprotectionneurosciencepeptidetransthyretin

Identifiers

PMID32769117
PMCPMC7549042
OpenAlexW3047897346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.